In situ hybridization is a powerful tool for detecting and analyzing gene expression in a variety of biological samples. This technique has been used extensively in the Asia-Pacific region for a variety of research purposes, ranging from basic biological research to clinical and diagnostic applications.
In situ hybridization combines the use of hybridization probes, which are single-stranded DNA or RNA molecules, with a variety of techniques such as immunocytochemistry or histochemistry, to detect and analyze the expression of specific genes in a biological sample. By combining these techniques, researchers are able to identify the location and expression levels of specific gene sequences in a variety of samples, including cells, tissues, and whole organisms.
Currently, APAC In Situ Hybridization Market is projected to reach USD 744 million by 2027 from USD 363 million in 2022, at a CAGR of 15.4% during the forecast period. The growth is largely driven by increasing government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics.
The market is segmented by type into enzymatic debridement, mechanical debridement, autolytic debridement, and others. The enzymatic debridement segment is expected to hold the largest market share over the forecast period, as it is the most widely used method for APAC In Situ Hybridization. Additionally, the rising demand for enzymatic debridement products and services is expected to drive the market growth.
The market is further segmented by end-use into hospitals, clinics, and homecare settings. Hospitals are expected to hold the largest share of the market, as they offer specialized services for APAC In Situ Hybridization. The increasing number of hospitals and clinics offering specialized wound care services is expected to fuel the market growth.
Request for assumptions & how numbers were triangulated.
Key drivers of the APAC in situ hybridization market include growing cases of cancer in the region coupled with rising incidence of genetic disorders. Moreover, growing adoption of companion diagnostics will also propel the market growth. However, lack of skilled professionals will hinder the market growth over the forecast period.
The FISH segment dominates the in situ hybridization (ISH) market through 2020-2027.
The Asia Pacific in situ hybridization market is segmented into product, technology, application, end user, and country. The FISH segment is expected to witness significant growth during the forecast period due to various advantages, such as high resolution, speed, safety, and cost-effectiveness. It has also paved the way for the development of simultaneous detection of multiple targets, quantitative analyses, and live-cell imaging.
In 2021, the hospitals and diagnostic laboratories ranked first in terms of revenue in the in situ hybridization market.
On the basis of end users, the APAC in situ hybridization market is segmented into academic & research institutes, hospitals and diagnostic laboratories, contract research organizations (CROs), and pharmaceutical & biotechnology companies. In 2021, the hospitals and diagnostic laboratories segment accounted for the largest share of the in situ hybridization market, owing to easy accessibility of hospital-based laboratories coupled with high patient footfall in the hospitals.Moreover, Diagnostic labs are equipped with advanced technologies and capabilities, such as efficient billing and collection management. They offer a lower cost per test and a higher level of automation.
In situ hybridization is an invaluable tool for researchers in the Asia-Pacific region, allowing them to gain insight into the biological processes that are taking place in their samples. This technique has enabled researchers to make significant advances in many areas of biology and medicine, and its use is likely to continue to expand and evolve as new techniques and technologies are developed.
In the Asia-Pacific region, in situ hybridization has been used to study a variety of topics, including gene expression in cancer and other diseases, microbial ecology, and plant development. In addition, in situ hybridization has been used to study the evolution and diversity of species, as well as the expression of genes in response to environmental changes.
Download an Illustrative Overview:
In 2022, RNAscope ISH Detection Kit manufactured by Bio-Techne received CE-IVD approval for the BOND-III platform (Leica Biosystems).
In 2021, Applied Spectral Imaging (ASI) and KromaTiD, Inc. entered a strategic commercial partnership granting ASI worldwide rights to market KromaTiD’s proprietary Pinpoint FISH (PPF) probes and assay services.